ONCY Key Statistics, Chart & Performance
The current stock price of ONCY is 0.9837 USD. In the past month the price increased by 8.52%. In the past year, price increased by 2.48%.
ONCY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About ONCY
Company Profile
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Company Info
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 29
Phone: 14036707377
ONCOLYTICS BIOTECH INC / ONCY FAQ
What does ONCOLYTICS BIOTECH INC do?
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
What is the stock price of ONCOLYTICS BIOTECH INC today?
The current stock price of ONCY is 0.9837 USD. The price increased by 12.55% in the last trading session.
Does ONCOLYTICS BIOTECH INC pay dividends?
ONCY does not pay a dividend.
What is the ChartMill rating of ONCOLYTICS BIOTECH INC stock?
ONCY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does ONCOLYTICS BIOTECH INC belong to?
ONCOLYTICS BIOTECH INC (ONCY) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for ONCY stock?
ONCOLYTICS BIOTECH INC (ONCY) currently has 29 employees.
What is ONCOLYTICS BIOTECH INC worth?
ONCOLYTICS BIOTECH INC (ONCY) has a market capitalization of 95.82M USD. This makes ONCY a Micro Cap stock.
ONCY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ONCY. When comparing the yearly performance of all stocks, ONCY is a bad performer in the overall market: 78.63% of all stocks are doing better.
ONCY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ONCY. ONCY may be in some trouble as it scores bad on both profitability and health.
ONCY Financial Highlights
Over the last trailing twelve months ONCY reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -8.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.26% | ||
| ROE | -499.46% | ||
| Debt/Equity | 0.1 |
ONCY Forecast & Estimates
8 analysts have analysed ONCY and the average price target is 3.32 USD. This implies a price increase of 237.44% is expected in the next year compared to the current price of 0.9837.